Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

被引：0

作者：

Merryman, Reid W. ^{[1
]}

Belada, David ^{[2
]}

Sureda, Anna ^{[3
]}

Leppa, Sirpa ^{[4
,5
]}

Vermaat, Joost S. P. ^{[6
]}

Holte, Harald ^{[7
,8
]}

Hutchings, Martin ^{[9
]}

Lugtenburg, Pieternella ^{[10
]}

de Vos, Sven ^{[11
]}

Abrisqueta, Pau ^{[12
]}

Nijland, Marcel ^{[13
,14
]}

Christensen, Jacob Haaber ^{[15
]}

Wahlin, Bjorn E. ^{[16
]}

Linton, Kim M. ^{[17
,18
]}

Wang, Liwei ^{[19
]}

Abbas, Aqeel ^{[19
]}

Rana, Ali ^{[19
]}

Quadri, Syed ^{[20
]}

Falchi, Lorenzo ^{[21
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[3] Univ Barcelona, Inst Catala Oncol, Hosp Duran Reynals, IDIBELL, Lhospitalet De Llobregat, Spain

[4] Univ Helsinki, Helsinki, Finland

[5] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland

[6] Leiden Univ, Med Ctr, Leiden, Netherlands

[7] Oslo Univ Hosp, Oslo, Norway

[8] KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[9] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[10] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[11] Ronald Reagan Univ Calif, Los Angeles Med Ctr, Los Angeles, CA USA

[12] Hosp Univ Vall Hebron, Barcelona, Spain

[13] Univ Med Ctr Groningen, Groningen, Netherlands

[14] Univ Groningen, Groningen, Netherlands

[15] Odense Univ Hosp, Odense, Denmark

[16] Karolinska Inst, Stockholm, Sweden

[17] Christie NHS Fdn Trust, Manchester, Lancs, England

[18] Manchester Canc Res Ctr, Manchester, Lancs, England

[19] Genmab, Princeton, NJ USA

[20] AbbVie, N Chicago, IL USA

[21] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; bispecific; follicular lymphoma; hematologic malignancy; non-Hodgkin lymphoma; phase I/II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-474

引用

页码：S454 / S454

页数：1

共 50 条

[31] Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma
Hill, Brian T.
Chen, Yanwen
Jagadeesh, Deepa
Dean, Robert
Koc, Omer
Boughan, Kirsten
Cooper, Brenda
Pohlman, Brad
Caimi, Paolo
Smith, Mitchell R.
LEUKEMIA & LYMPHOMA, 2024, 65 (06) : 768 - 773
[32] Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?
Etto, Leina Yukari
Silva, Vanderleia Costa
Inaoka, Riguel Jun
Costa, Roberta Pasianotto
Alves, Antonio Correa
Colleoni, Gisele W. B.
LEUKEMIA & LYMPHOMA, 2007, 48 (03) : 526 - 530
[33] Subcutaneous Epcoritamab in Combination with Rituximab plus Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
Falchi, Lorenzo
Leslie, Lori A.
Belada, David
Kopeckova, Katerina
Offner, Fritz
Brody, Joshua
Canales, Miguel
Martin Garcia-Sancho, Alejandro
Nijland, Marcel
Andersson, P-O
Awan, Farrukh T.
Christensen, Jacob Haaber
Drott, Kristina
Hellstrom, Mats
Lewerin, Catharina
Narkhede, Mayur
Snauwaert, Sylvia
Wahlin, Bjorn E.
Rana, Ali
Abbas, Aqeel
Wang, Liwei
Minh Dinh
Vermaat, Joost S. P.
Abrisqueta, Pau
BLOOD, 2022, 140 : 1471 - 1473
[34] Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
Wang, Michael
Munoz, Javier
Goy, Andre
Locke, Frederick Lundry
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian
McSweeney, Peter A.
Miklos, David Bernard
Kersten, Marie Jose
Bouabdallah, Krimo
Topp, Max S.
Shen, Rhine
Kloos, Ioana
Peng, Weimin
Fang, Xiang
Reagan, Patrick M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Subcutaneous Epcoritamab Combined With R-CHOP for First-Line Treatment of Patients With High-Risk Diffuse Large B-Cell Lymphoma: Phase 1/2 Update
Lorenzo, Falchi
Fritz, Offner
David, Belada
Joshua, Brody
Linton, Kim M.
Yasmin, Karimi
Raul, Cordoba
Sylvia, Snauwaert
Aqeel, Abbas
Liwei, Wang
Jun, Wu
Brian, Elliott
Clausen, Michael R.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S30 - S30
[36] Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: Experience on 142 patients
Zinzani, Pier Luigi
Pellegrini, Cinzia
Broccoli, Alessandro
Casadei, Beatrice
Argnani, Lisa
Pileri, Stefano
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (11) : E273 - E276
[37] A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma
Noel, Robin
Zemmour, Christophe
de Oca, Catalina Montes
Belmecheri, Nawel
Aurran-Schleinitz, Therese
Coso, Diane
Almeida, Leonor Lopez
Mescam, Lenaig
Vey, Norbert
Blade, Jean Sebastien
Slama, Borhane
Bouabdallah, Reda
de Colella, Jean-Marc Schiano
HEMATOLOGY, 2023, 28 (01)
[38] BORTEZOMIB PLUS RITUXIMAB (VCR) VS RITUXIMAB ALONE (R) IN PATIENTS (PTS) WITH HIGH-RISK, RELAPSED FOLLICULAR LYMPHOMA (FL)
Zinzani, P. L.
Khuageva, N. K.
Wang, H.
Garikochea, B.
Walewski, J.
Van Hoof, A.
Soubeyran, P.
Caballero, D.
Okada, C. Y.
Buckstein, R.
Esseltine, D. L.
Theocharous, P.
Enny, C.
Zhu, E.
Elsayed, Y. A.
Coiffier, B.
ANNALS OF ONCOLOGY, 2011, 22 : 186 - 186
[39] Epcoritamab plus R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Karimi, Yasmin
Abrisqueta, Pau
de Vos, Sven
Nijland, Marcel
Offner, Fritz
Osei-Bonsu, Kojo
Rana, Ali
Archer, Kimberly G.
Song, Yaou
Cordoba, Raul
Falchi, Lorenzo
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[40] Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24).
Jacobson, Caron A.
Chavez, Julio C.
Sehgal, Alison
William, Basem M.
Munoz, Javier
Salles, Gilles A.
Casulo, Carla
Munshi, Pashna N.
Maloney, David G.
De Vos, Sven
Reshef, Ran
Leslie, Lori Ann
Yakoub-Agha, Ibrahim
Oluwole, Olalekan O.
Fung, Henry Chi Hang
Plaks, Vicki
Yang, Yin
Lee, Jennifer
Avanzi, Mauro P.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →